Search

Your search keyword '"Saiag, Philippe"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Saiag, Philippe" Remove constraint Author: "Saiag, Philippe" Database ScienceDirect Remove constraint Database: ScienceDirect
47 results on '"Saiag, Philippe"'

Search Results

1. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

2. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study

3. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

5. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

6. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

7. Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma

8. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

9. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

11. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

12. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

14. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

15. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network

16. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

17. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns

20. Impact of adjuvant radiation therapy on survival and recurrence in patients with stage I-III Merkel cell carcinoma: A retrospective study of 312 patients

24. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas

26. Différentiel d’efficacité de l’immunothérapie selon le profil d’exposition solaire du site de survenue du mélanome primitif : étude de cohorte prospective multicentrique MELBASE

29. Risque de toxicité immunomédiée chez les patients avec antécédents d’auto-immunité traités par inhibiteurs de checkpoint pour un mélanome métastatique

30. La radiothérapie adjuvante est associée à une diminution du risque de mortalité et de récidive dans le traitement initial du carcinome de Merkel stades I-III : étude rétrospective muticentrique

31. Les inhibiteurs de checkpoint immunitaires sont associés à une amélioration de la survie chez des patients atteints de carcinome de Merkel avancé ou métastatique : résultats d’une cohorte en vie réelle de 98 patients

34. Étude d’un algorithme adapté de gestion de la fièvre chez les patients traités par dabrafénib + tramétinib en adjuvant : premiers résultats de la cohorte française de COMBI-APlus

35. Résultats finaux d’une cohorte de 705 patients atteints de mélanome avancé et ayant débuté un traitement par pembrolizumab au cours de son programme français d’ATU

41. Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies

46. Ont collaboré à cet ouvrage

Catalog

Books, media, physical & digital resources